K
Kodiak Sciences D
D
KOD
32.690
USD
-0.20
(-0.61%)
Post Trading·32.720USD+0.030(+0.09%)
حجم التداول
25,457
الربح لكل سهم
-4
العائد الربحي
-
P/E
-8
حجم السوق
2,054,548,749
العنوان: Kodiak Sciences
القطاع: الرعاية الصحية
الصناعة: Biotechnology
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.